Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic...

Area of Science:

• Oncology
• Molecular Biology
• Proteomics

Background:

• Medulloblastoma comprises four main subgroups, extensively studied at genomic and transcriptomic levels.
• The proteome and phosphoproteome landscapes of these subgroups remain incompletely understood.
• Understanding these landscapes is crucial for identifying subgroup-specific oncogenic drivers.

Purpose of the Study:

• To comprehensively elucidate the proteome and phosphoproteome of medulloblastoma subgroups.
• To identify distinct posttranscriptional regulatory mechanisms driving oncogenic signaling in different subgroups.
• To uncover potential therapeutic vulnerabilities in group 4 medulloblastoma.

Main Methods:

• Quantitative proteomics and phosphoproteomics were employed on primary human medulloblastomas.
• Integrative proteogenomic analysis was used to correlate proteomic data with genomic and transcriptomic profiles.
• Murine models were utilized to validate findings by enforcing specific signaling pathways.

Main Results:

• Distinct posttranscriptional regulation and divergent oncogenic signaling were identified between group 3 and group 4 medulloblastomas.
• Aberrant ERBB4-SRC signaling was specifically identified in group 4 medulloblastoma.
• Enforced SRC activation and p53 inactivation in mice recapitulated key features of group 4 medulloblastoma.

Conclusions:

• The study reveals a novel oncogenic pathway involving ERBB4-SRC signaling in group 4 medulloblastoma.
• This pathway represents a potential therapeutic vulnerability in the most common medulloblastoma subgroup.
• Integrative proteogenomics provides critical insights into medulloblastoma heterogeneity and targeted therapy development.